Here, our results unveil a previously undescribed role for MECOM in the transcriptional regulation of KRAS oncogene at chromatin level, consolidating its importance as a relevant target for therapeutic intervention in ovarian cancer. This evidence concerns the gene KRAS and ovarian cancer.